Home › Funds › PERCEPTIVE ADVISORS LLC › NAMS
PERCEPTIVE ADVISORS LLC position in NAMS
NEWAMSTERDAM PHARMA COMPANY · Health Care
PERCEPTIVE ADVISORS LLC reported holding 600,000 shares of NAMS (NEWAMSTERDAM PHARMA COMPANY) in its Q3 2026 13F filing — a position valued at US$14.6M, representing 0.28% of its reported portfolio and ranking #50 among its reported holdings. PERCEPTIVE ADVISORS LLC has disclosed NAMS holdings in 3 of the last 11 reported quarters, going back to Q1 2024.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How PERCEPTIVE ADVISORS LLC's NAMS position evolved
PERCEPTIVE ADVISORS LLC first disclosed a stake in NAMS in Q1 2024 at 175,000 shares (US$4.1M). The position peaked in Q2 2026 at 500,000 shares, worth US$16.9M. Across 3 filings, PERCEPTIVE ADVISORS LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 600,000 shares valued at US$14.6M — an increase of 100,000 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2024 | 175.00K | $4.14M | New |
| Q2 2026 | 500.00K | $16.95M | New |
| Q3 2026 | 600.00K | $14.59M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About NAMS and 13F data
NAMS (NEWAMSTERDAM PHARMA COMPANY) is a Health Care company. 35 other funds we track also report a position in NAMS — the largest reported positions include Frazier Life Sciences Management, L.P. (US$461.8M), RA CAPITAL MANAGEMENT, L.P. (US$232.3M), FCPM III SERVICES B.V. (US$206.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding NAMS
- Frazier Life Sciences Management, L.P. 18.99M sh · $461.81M · Q3 2026
- RA CAPITAL MANAGEMENT, L.P. 9.55M sh · $232.26M · Q3 2026
- FCPM III SERVICES B.V. 8.49M sh · $206.49M · Q3 2026
- Maverick Capital 3.27M sh · $110.75M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 4.25M sh · $103.46M · Q3 2026
- Bain Capital Life Sciences Investors, LLC 3.81M sh · $92.58M · Q3 2026
- Duquesne Family Office LLC 3.36M sh · $81.65M · Q3 2026
- Medicxi Ventures Management (Jersey) Ltd 2.18M sh · $53.07M · Q3 2026
- MAVERICK CAPITAL LTD 1.86M sh · $45.13M · Q3 2026
More on PERCEPTIVE ADVISORS LLC
FAQ
How long has PERCEPTIVE ADVISORS LLC held NAMS?
PERCEPTIVE ADVISORS LLC has disclosed NAMS holdings in 3 of the last 11 reported quarters, going back to Q1 2024.
What is PERCEPTIVE ADVISORS LLC's current position in NAMS?
As of Q3 2026, PERCEPTIVE ADVISORS LLC holds 600.00K shares of NAMS (NEWAMSTERDAM PHARMA COMPANY), valued at $14.59M, representing 0.28% of its reported portfolio and ranking #50.
Has PERCEPTIVE ADVISORS LLC been buying or selling NAMS?
In the latest 13F filing (Q3 2026), PERCEPTIVE ADVISORS LLC increased its position in NAMS. The position peaked in Q2 2026 at 500.00K shares.
Which other funds hold NAMS?
Other major institutional holders of NAMS include Frazier Life Sciences Management, L.P., RA CAPITAL MANAGEMENT, L.P., FCPM III SERVICES B.V., among 35 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.